Comparative Pharmacology
Head-to-head clinical analysis: AMBIEN CR versus EDLUAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBIEN CR versus EDLUAR.
AMBIEN CR vs EDLUAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMBIEN CR's active ingredient is zolpidem, a non-benzodiazepine hypnotic that binds selectively to the benzodiazepine-1 (BZ1) receptor subtype on the GABA-A receptor complex, potentiating GABAergic inhibition and promoting sleep.
Zolpidem is a non-benzodiazepine hypnotic that acts as a positive allosteric modulator of GABA-A receptors, specifically binding to the alpha1 subunit, enhancing chloride ion conductance and producing sedative effects.
12.5 mg orally once daily immediately before bedtime; lower dose of 6.25 mg may be considered. Not to exceed 12.5 mg per day.
10 mg sublingually once daily at bedtime for insomnia; maximum 10 mg per night.
None Documented
None Documented
Zolpidem immediate-release: ~2.5 h (range 1.4–3.8 h); modified-release (Ambien CR): ~2.8 h (range 1.6–4.5 h). Clinical note: Half-life increased in hepatic impairment and elderly.
Terminal elimination half-life is approximately 2 hours (range 1.5–3 hours). This short half-life supports its use for sleep induction with minimal next-day residual effects.
Primarily renal (80% as metabolites, <5% unchanged), minor fecal (<10%)
Primarily renal, with approximately 80% of the dose excreted in urine as metabolites (mostly glucuronide conjugates) and less than 1% as unchanged drug. Fecal excretion accounts for <15%.
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic